1Lordkipanidze M,Pharand C, Palisaitis DA, et al. Aspirin resistance : truth or dare[J]. Pharmacol Ther, 2006,112 : 733-743.
2Bhatt D, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy[J]. Nature Rev, 2003,2 : 15-28.
3WeberA A, Przytulski B, Schanz A, et al. Towards a definition of aspirin resistance: a typological approach[J]. Platelets, 2002.13,37- 40.
4Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease[J]. Am J Med, 2005,118 : 723-727.
5Zczeklik A, Musia J, Undas A, et al. Aspirin resistance [J]. J ThrombHaemost,2005,3:1655- 1662.
6Horiuchi H. Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems [J]. Ann Med, 2006,38: 162-172.
7Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance [J]. J Thromb Thrombol,2002,13 :49-56.
8Ulrich CM, Bigler J, Sibert J, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations[J]. Hum Mutat, 2002,5 : 409-410.
9Maree AO, Curtin RJ , Chubb A, et al. Cyclooxygenase-1 hap lotype modulates platelet response to aspirin[J]. J Thromb Haemost,2005,3:2 340-2 345.
10Gonzalez-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure [J].Stroke,2005,36 : 276- 280.
9Juan JB,Deepak LB,Jean Marc H.Clinical evidence for antiinflam-matory effects of antiplatelet therapy in patients with atherothrom-botic disease[J].Vascular Medicine,2007,12(2):113-122.
10Chung SM,Bae ON,Lim KM,et al.Lysophosphatidic acid inducesthrombogenic activity through phosphatidylserine exposure andprocoagulant microvesicle generation in human erythrocytes[J].Arterioscler Thromb Vasc Biol,2007,27(2):414-421.
